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Abstract
The paramyxoviruses are a family of negative-sense RNA viruses that includes many important human and animal pathogens.
ParamyxovirusRNAsynthesisrequirestheviralphosphoprotein (P)andthe large (L)protein.Phosphorylation ofP isthoughtto
regulate viral gene expression, though direct proof remains elusive. Recently, we reported that phosphorylation of a specific
residue (Ser157) of the P protein of parainfluenza virus 5 (PIV5), a prototypical paramyxovirus, correlates with decreased viral
gene expression and cytokine expression in infected cells. Here, we show that: Polo-like kinase 1 (PLK1), a serine/theronine
kinase that plays a critical role in regulating the cell cycle, interacts with PIV5 P through the S157 residue; PLK1 inhibition
increases viral gene expression; PLK1 over-expression inhibits viral gene expression; and PLK1 directly phosphorylates P in
vitro, indicating that PLK1 down-regulates viral gene expression by phosphorylating P. Furthermore, we have determined the
PLK1 phosphorylation site on P and found that mutant recombinant PIV5 whose P proteins cannot either bind to or be
phosphorylated by PLK1 have similar phenotypes. Increased viral gene expression in PIV5 with mutations in the PLK1 binding/
phosphorylation sites correlates with increased induction of cell death and cytokine expression, suggesting that PIV5 limits its
viral gene expression to avoid these host effects. It is possible thattargeting PLK1 will enhancehost innate immune responses,
leading to a novel strategy of clearing paramyxovirus infections quickly.
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Introduction
Viruses in the Paramyxoviridae family of Mononegavirales include
many important human and animal pathogens such as the human
parainfluenza viruses, Sendai virus (SeV), mumps virus (MuV),
Newcastle disease virus (NDV), measles virus (MeV), rinderpest
virus and human respiratory syncytial virus (RSV) as well as the
emerging viruses Nipah and Hendra virus. The paramyxovirus
RNA-dependent RNA polymerase (RdRp), which both transcribes
and replicates the viral RNA genome, consists of two proteins, the
phosphoprotein (P) and the large (L) protein [1]. While
paramyxovirus P proteins are all heavily phosphorylated (hence
the name phosphoprotein) and are essential for viral gene
expression, the role of P phosphorylation in the replication of
paramyxoviruses remains an enigma. Conclusive evidence on the
role of phosphorylation of the P protein in replication of
paramyxoviruses remains elusive. The most recent work seems
to indicate that the phosphorylation of the P proteins of
paramyxoviruses does not have a role in viral gene expression.
The best-studied P proteins of paramyxoviruses are the P proteins
of RSV and SeV. It was first reported in the 1970s that the P
protein of SeV is phosphorylated [2]. While as many as 11
phosphorylation sites were detected, the serine (Ser) residue at
position 249 was determined to be the major phosphorylation site
[3]. However, recombinant SeV containing mutations at the
major P phosphorylation sites have similar growth characteristics
and pathogenicity in vitro (cultured cells) and in vivo (mice) [4],
indicating that these sites are not important for viral gene
expression. Mutating five additional phosphorylation sites besides
S249 results in a P mutant whose level of phosphorylation is
reduced by more than 90% in transfected cells; yet, the mutant P
still has normal activity in a mini-genome system [5]. The P
protein of RSV is the most heavily phosphorylated of the
paramyxovirus P proteins [6]. Two clusters of phosphorylation
sites (amino acid residues 116, 117 and 119 and residues 232 and
237) have been identified [7–10]. When mutations are introduced
into these sites in recombinant RSV by a reverse genetics system,
expression levels of the viral genes are not adversely affected,
indicating that these residues do not play a critical role in viral
gene expression [11]. Further studies of the P protein using mass
spectrometry identified the threonine residue at position 108 as
being phosphorylated. The phosphorylation of T108 is important
for its interaction with M2-1, a processivity factor of viral RNA
synthesis, and mutating this residue results in diminished activity
in a mini-genome system, suggesting that P may regulate viral
RNA synthesis through its interaction with M2-1 [12]. However,
the role of this phosphorylation site has not been examined in the
context of virus infection. The P protein of HPIV3 is phosphor-
ylated by protein kinase C isoform f (PKC-f) [13] and the serine
residue at position 333 is the likely target site [14]. However, the
role of phosphorylation at Ser 333 in the virus life cycle has not
been reported. Thus, to the best of our knowledge, regulation of
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has never been directly demonstrated in virus-infected cells even
though it is thought that the phosphorylation of the P protein is
critical for its function in viral gene expression.
PIV5, formerly known as simian virus 5 (SV5) [15], is a
prototypical paramyxovirus of the Rubulavirus genus of the family
Paramyxoviridae [1]. The PIV5 genome encodes seven genes, from
which eight viral proteins are made [1]. The nucleocapsid protein
(NP), phosphoprotein (P) and large RNA polymerase (L) protein
are essential for viral RNA synthesis (mRNA transcription and
genome RNA replication). The V protein plays important roles in
viral pathogenesis. The V/P gene of PIV5 is transcribed into both
the V mRNA and the P mRNA through a process of pseudo-
templated addition of nucleotides, in which the V mRNA is made
by faithful transcription the V/P gene and the P mRNA is made
by co-transcriptional insertion of two non-templated G residues at
a specific site. As a result, the V/P gene is transcribed into two
mRNAs and translated into two proteins, which share identical N-
termini (164 amino acid residues) but different C-termini.
Previously, a strain of PIV5, called canine parainfluenza virus
(CPI+), that causes a neurological disorder in canines was isolated
[16]. During the course of studying the CPI+ virus, a derivative of
CPI+, termed CPI2, was isolated from a dog that was
experimentally infected with the CPI+ virus [17]. Several
differences were found among the genomes of CPI+, CPI2 and
the commonly used lab strain, W3A, including in the shared
region of the V/P gene [15,18,19]. The CPI2 virus has eight
amino acid residues in the V/P gene that are different from the
W3A strain (referred to as wild type in this work) and six of them
are in the shared region of the V and the P proteins (the N-
terminus 164 amino acid residues). The CPI+ virus has five amino
acid residues different from wild type PIV5 in the V/P gene and
three of them are in the shared region of the V and P proteins
(Fig. 1A). A recombinant PIV5 (W3A strain) containing the CPI2
mutations in the shared V and P proteins (rPIV5-CPI2) was
shown to have elevated viral gene expression compared to the wild
type W3A strain and to induce expression of host anti-viral
response genes, such as interferon (IFN)-b and interleukin (IL)-6,
and apoptosis in infected cells [20]. Our recently work indicates
that a single amino acid residue of P, the serine at position 157
(S157), is responsible for the increased viral gene expression. S157
is phosphorylated and its phosphorylation correlates with
decreased viral gene expression as well as the lack of induction
of cytokine expression in infected cells [21], suggesting that
phosphorylation at S157 plays a role in regulating viral gene
expression. However, mechanism of this regulation is not clear.
Intriguingly, S157 residue of P is within a consensus binding
motif for Polo-like kinase 1 (PLK1), a serine/theronine kinase that
plays a critical role in regulating the cell cycle [22]. PLK1 contains
two domains, a polo-box domain (PBD) and a kinase activity
domain. It is known that the PBD domain of PLK1 binds to its
target through a SpS(orT)P motif (SSP motif), where the second
amino acid residue, S or T, is phosphorylated for optimal binding
[23]. The binding of PLK1 to a target protein with an SSP motif
enables PLK1 to phosphorylate either the target itself or a protein
associated with the target [24]. Here, we have investigated the role
of PLK1 in the increased viral gene expression of rPIV5-CPI2.
Results
PLK1 interacts with P in both infected and transfected
cells via the SSP motif
Previously, it has been reported that rPIV5-CPI+, a recombinant
virus containing three amino acid changes (V32I, T33I, and S157F)
compared to wild type has elevated viral gene expression levels and
that S157F is responsible for the phenotype [21]. To ascertain the
mechanism of the increased viral gene expression, the amino acid
sequence of P was searched for known motifs. S157 is in a PLK1
binding motif [23,25], suggesting that PLK1 may play a role in
regulating viral gene expression. To investigate a possible role of
PLK1 in viral gene expression, we examined the interaction
between PLK1 and P. HeLa cells were mock-infected or infected
with PIV5 or rPIV5-CPI+. The cell lysates were immunoprecip-
itated with anti-P antibody and then immunoblotted with anti-P or
anti-PLK1 antibody. As shown in Fig. 1B, PIV5 P protein
interacted with endogenous PLK1, while P protein of rPIV5-
CPI+ (Pcpi+) didnot. SinceP interactswith viralproteinsNPandL,
we wanted to determine whether PLK1 interacts directly with P.
Therefore, we examined the interaction between PLK1 and P in
transfected cells. As shown in Fig. 1C, PLK1 was co-immunopre-
cipitated with P, but not with Pcpi+ by antibody against P; the
reciprocal immunoprecipitation with anti-Flag antibody confirmed
the interaction of PLK1 withP and not Pcpi+, indicating that PLK1
interacts with P, likely through the SSP motif centered at the residue
S157. Furthermore, we carried out the same experiments using
immunoprecipitation followed by immunoblottingand obtained the
same results (supplemental Fig. S1).
PLK1 down-regulates PIV5, but not rPIV5-CPi+ gene
expression
To investigate the role of PLK1 in PIV5 gene expression, we
tested the effect of a PLK1 inhibitor (BI 2536) on reporter gene
expression using a recombinant PIV5 expressing Renilla luciferase,
(rPIV5-RL). As shown in Fig. 2A, BI 2536 at 0.05 and 1 mM
increased Renilla luciferase activity in HeLa cells. In BSR T7 cells,
BI2536 was also effective in increasing the luciferase activity, albeit
at higher concentrations. Because of concerns over potential off-
target effects of this molecule, we also tested the effect of a
structurally different PLK1 inhibitor, GW843682 (Sigma), in
HeLa cells and found the same effect on reporter gene expression
as observed with BI 2536 (supplemental Fig. S2). Furthermore, we
examined the effect of PLK1 inhibition on viral protein
expression. HeLa cells were infected and then metabolically
labeled with
35S-Cys/Met. The infected cells were immunopre-
cipitated with antibody (Pk) that recognizes both the P and V
protein. Compared with control, BI 2536 treatment increased
PIV5 viral protein expression (Fig. 2B) (NP and L bind to P and
Author Summary
The paramyxoviruses are a family of negative-sense RNA
viruses that includes many important human and animal
pathogens. Paramyxovirus RNA synthesis requires the viral
phosphoprotein (P) and the large (L) protein. Phosphory-
lation of P is thought to regulate viral gene expression,
though direct proof remains elusive. Here, we show that
Polo-like kinase 1 (PLK1) interacts with the P protein of
parainfluenza virus 5 (PIV5), a prototypical paramyxovirus,
through the serine residue at position 157 and phosphor-
ylates P at serine residue 308. Inhibition of PLK1 increases
viral gene expression. Increased viral gene expression in
cells infected by PIV5 with mutations in the PLK1 binding/
phosphorylation sites correlates with increased induction
of cell death and cytokine expression, suggesting that PIV5
limits its gene expression to avoid induction of innate
immune responses. It is possible that targeting PLK1 will
enhance host innate immune responses, leading to a novel
strategy of anti-paramyxovirus therapy.
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BI 2536 treatment did not greatly affect cellular protein
expression, as shown in the right panel in Fig. 2B, indicating that
PLK1 regulation of gene expression in infected cells is specific to
PIV5. Interestingly, BI 2536 did not increase viral protein
expression in rPIV5-CPI+-infected cells (Fig. 2C), suggesting that
PLK1 does not play a role in regulating viral gene expression of
rPIV5-CPI+. These results suggest that the SSP motif plays a
critical role in the inhibition of viral gene expression by PLK1. To
further examine the role of PLK1 in viral gene expression, we used
a mini-genome system, in which viral gene expression can be
examined free of viral infection [21]. As shown in Fig. 2D, PLK1
inhibitor BI 2536 increased reporter gene activity from the PIV5
mini-genome using wt P, but had little effect on luciferase
expression driven by Pcpi+. This result is consistent with the
observation in infected cells. We also attempted to utilize siRNA
technology to knock down expression of endogenous PLK1 in
HeLa cells (data not shown) to examine the effect PLK1 depletion
on viral gene expression. Unfortunately, the experiment was
inconclusive due to the toxicity of siRNA against PLK1. Optimal
knock down of PLK1 expression occurs between 48 to 96 hours
after transfection of siRNA, after which we infected the siRNA-
treated cells. Since PLK1 plays a critical role in cell cycle
progression, this long period of PLK1 depletion, coupled with viral
infection, is overwhelmingly cytotoxic.
Since phosphorylation of S157 reduces activity of the P protein,
we reasoned that increased phosphorylation of the residue by
PLK1 overexpression would further reduce the activity of P. When
PLK1 was ectopically expressed in the mini-genome system, PLK1
transfection reduced the mini-genome activity in a dose dependent
manner (Fig. 2E): there was about 50% reduction of luciferase
activity using 2 ng, and 95% reduction with 16 ng, of PLK1
plasmid in the transfection. PLK1 overexpression had a much
weaker effect on mini-genome transcription when Pcpi+ was used
in place of wild type P; PLK1 plasmid at 4 ng, 8 ng and 16 ng
moderately inhibited the Pcpi+ mini-genome activity, while there
was no significant effect at 2 ng though expression levels of PLK1
correlated with amount of plasmids transfected. To confirm that
PLK1 binds the SSP motif, we performed similar experiments
using P containing a single point mutation S157A instead of Pcpi+,
which has three point mutations (V32I, T33I, and S157F). As
expected, P-S157A failed to bind PLK1 (supplemental Fig. S3A)
and the mini-genome activity using P-S157A was weakly affected
by PLK1 over-expression (supplemental Fig. S3B). Those data
Figure 1. Interaction between P and PLK1. (A). Amino acid residue differences among N-termini of wild type P, Pcpi2 and Pcpi+. (B). Interaction
between P and endogenous PLK1 in infected cells. HeLa cells were infected with mock, PIV5 or rPIV5-CPI+ and immunoprecipitated (IP) with anti-P
antibody. The immunoprecipitated proteins were resolved in SDS-PAGE and subjected to immunoblotting (IB) with antibody against PLK1. (C).
Interaction between P and PLK1 in transfected cells. BSR T7 cells were transfected with plasmids encoding P or Pcpi+ along with Flag-PLK1. Vector
(pCAGGS) was used to keep the total amount of transfected plasmids constant. At 18–20 hours post transfection, the transfected cells were
metabolically labeled with
35S-Cys/Met for 3 h at 37uC. The cells were lysed by RIPA buffer and immunoprecipitated with Pk antibody or Flag
antibody. The precipitated proteins were resolved by SDS-PAGE gel and visualized using a PhosphorImager.
doi:10.1371/journal.ppat.1000525.g001
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PLoS Pathogens | www.plospathogens.org 3 July 2009 | Volume 5 | Issue 7 | e1000525Figure 2. Effects of PLK1 inhibitor and over-expression of PLK1 on viral gene expression. (A). Effect of PLK1 inhibitor BI 2536 on
recombinant PIV5 expressing Renilla luciferase (rPIV5-RL). HeLa or BSR T7 cells in 24-well plates were infected with rPIV5-RL at MOI of 1 and incubated
with BI 2536 at concentration of 0.01, 0.05, 0.1, 0.2, 0.5 and 1 mM. Renilla luciferase activity was measured at 18–20 hours post infection and average
luciferase activity +/2 standard derivation of mean (SEM) is shown. (B). Effect of PLK1 inhibitor BI 2536 on viral gene expression. HeLa cells were
mock-infected or infected with PIV5 or rPIV5-CPI+ and incubated in 1 mM BI 2536. The cells were metabolically labeled with
35S-Met/Cys at 18–
20 hours after infection and immunoprecipitated with Pk antibody, which recognizes V and P and co-precipitates NP and L. The right panel is labeled
cell lysates without immunoprecipitation. (C). Quantification of Figure 2B. Six independent experiments were performed and the relative amount of
the P protein was measured. The level of PIV5 P in infected cells with DMSO treatment was set at 100 and the rest was normalized to the level of PIV5
P. The average of relative expression level of P +/2 SEM is shown. (D). Effects of PLK1 inhibitor on the mini-genome system. A mini-genome plasmid
(pSMG-RL) that contains a Renilla luciferase (RL) reporter gene and from which a negative-sense mini-genome is generated from T7 RNA polymerase
transcription in BSR T7 cells was described previously [21]. In the presence of NP and L and P or P from rPIV5-CPI+ (Pcpi+), this negative-sense RNA
template is replicated and transcribed to give rise to the RL mRNA, resulting in luciferase activity. The pT7-FF-Luc plasmid, which contains an FF-Luc
reporter gene as a transfection efficiency control, was transfected along with the plasmids. Firefly and Renilla luciferase activities were detected in cell
lysates at 18 to 20 h post-transfection, as described in Experimental Procedures. BSR T7 cells were transfected with necessary plasmids and incubated
with 0.25 mM BI 2536. At 18–20 hours post transfection, the cells were lysed and dual luciferase assay was performed. The relative luciferase activities
are calculated at ratios of Renilla luciferase activity (indicative of mini-genome replication) versus FF-Luc activity (indicative of transfection efficiency).
The average of relative luciferase activity +/2 SEM is shown. (E). Effects of PLK1 overexpression on the mini-genome system. Plasmids encoding
pCAGGS-Flag-PLK1 at various concentrations were transfected along with the mini-genome system as above. Dual luciferase assay was carried as
described above. An aliquot of cell lysate was used for immunoblotting to detect expression levels of Flag-PLK1 (the bottom panel).
doi:10.1371/journal.ppat.1000525.g002
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centered at the residue S157 and reduces PIV5 gene expression.
The moderate inhibitory effect of over-expressed PLK1 on Pcpi+
or P-S157A mini-genome system is likely due to an interaction
between PLK1 and an additional SS(T)P sequence centered at
T108 of P. This STP sequence is not known to be phosphorylated
and mutating this T to A had no effect on PLK1 binding or viral
gene expression (data not shown). However, since even unpho-
sphorylated STP can weakly interact with PLK1, overexpression
of PLK1 may result in interaction of PLK1 (a low level of Pcpi+
and PLK1 was indeed detected when PLK1 was overexpressed in
supplemental Fig. S1), resulting in the moderate inhibitory effect.
Kinase activity of PLK1 is required for its inhibitory effect
on PIV5 gene expression
To examine whether the binding of PLK1 is sufficient for its
inhibitory effect on PIV5 gene expression, or if its kinase activity is
required, we tested a the effect of overexpression of a kinase-
deficient PLK1 (PLK1-K82M), which has a lethal point mutation
at the ATP binding site (K82M), on PIV5 minigenome activity
[26]. As shown in Fig. 3A, PLK1-K82M, at amounts from 2 to
16 ng, failed to inhibit PIV5 mini-genome activity, in contrast to
wt PLK1, even though PLK1 and PLK1-K82M were expressed at
similar levels, indicating that kinase activity is required for PLK1’s
inhibitory effect on PIV5 gene expression. Since the binding
between PLK1 and target protein is through the PBD domain at
the C-terminus of PLK1, we expected that PLK1-K82M would
still bind the P protein and this was confirmed by co-
immunoprecipitation (Fig. 3B). Thus, the kinase activity of
PLK1 is required for PLK1’s effect on PIV5 gene expression,
while the binding itself is not sufficient.
PLK1 phosphorylates the P protein in infected cells
To investigate the mechanism by which PLK1 regulates PIV5
gene expression by PLK1, it was important to determine the
phosphorylation target of PLK1. PLK1 can phosphorylate SSP
motif-containing proteins themselves or those proteins associated
with the SSP-containing protein. We hypothesized that after
binding to the P protein, PLK1 phosphorylates P itself in infected
cells. To test this, we compared the level of phosphorylated P
protein with or without PLK1 inhibitor BI 2536 treatment in PIV5
or rPIV5-CPI+ infected cells. Consistent with previous studies
[21], rPIV5-CPI+ infected cells showed higher levels of viral
protein expression than that PIV5 infected cells and Pcpi+ had
lower level of phosphorylation than that of PIV5 (Fig. 4A). Because
we only treated the infected cells for a short period of time during
labeling (4 hours), no significant difference of PIV5 viral protein
levels between DMSO and BI 2536 treated cells was detected by
35S-Cys/Met labeling. However, there was a significant reduction
of phosphorylation of P due to BI 2536 treatment in PIV5 infected
cells (Fig. 4B), but not in rPIV5-CPI+ infected cells. Interestingly,
while NP was also phosphorylated in infected cells, its phosphor-
ylation was not affected by PLK1 inhibitor treatment, indicating
that NP phosphorylation is PLK1-independent even though it
interacts with P.
PLK1 phosphorylates the P protein at S308
Because PLK1 inhibition reduced P phosphorylation, we
wanted to determine the PLK1 phosphorylation site within P.
Since a consensus PLK1 phosphorylation site has been reported
[27], we searched the sequence of P and found that the serine
residue at position 308 (S308) within P protein resembles a PLK1
phosphorylation site (Fig. 5A). Mutation of S308 should thus result
in a P with higher activity in the mini-genome system that is
insensitive to PLK1. As shown in Fig. 5B, mutating S to A at 308
(P-S308A) increased the mini-genome activity when compared
with wild type P. Mutating S304 and S313, two other S residues
close to S308, had no effect on the mini-genome activity
(supplemental Fig. S4A and S4B). In addition, PLK1 inhibitor
BI 2536 treatment did not affect P-S308A mini-genome activity
(Fig. 5C). Furthermore, overexpression of PLK1 had no effect on
the activity of the mini-genome system using P-S308A (Fig. 5D),
Figure 3. Effect of kinase-deficient PLK1 on PIV5 protein expression. (A). Effects of overexpression of PLK1 kinase-dead mutant K82M on the
mini-genome system. BSR T7 cells in 24-well plates were transfected with various concentrations of pCAGGS-Flag-PLK1 or pCAGGS-Flag-PLK1-K82M
together with the plasmids necessary for the PIV5 mini-genome system. Dual luciferase assay was carried out after 18–20 h post transfection as
before. NC: negative control, no plasmid encoding P; PC: positive control, no plasmid encoding PLK1 or PLK1 K82M. The relative activity unit of
positive control was set as 100. The average of relative luciferase activity +/2 SEM is shown. An aliquot of cell lysates was used for immunoblotting to
detect the expression level of Flag-PLK1 or Flag-PLK1-K82M. (B). Interaction between P and PLK1-K82M. A plasmid encoding P was transfected into
cells with a plasmid encoding Flag-PLK1 or Flag-PLK1-K82M. The cells were metabolically labeled and immunoprecipitated with anti-P or anti-Flag.
doi:10.1371/journal.ppat.1000525.g003
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the possibility that the mutation at S308 caused a conformational
change in P such that it can no long be bound by PLK1, we
examined the interaction between PLK1 and P-S308A. As shown
in Fig. 5E, P-S308A co-precipitated with PLK1 and vice versa.
To confirm that PLK1 phosphorylates P protein at S308, we
carried out an in vitro kinase assay. P proteins were purified from
HeLa cells transfected with plasmids encoding either P or P-
S308A by affinity chromatography using anti-P antibody conju-
gated agarose gel. Purified P was then incubated with PLK1
purchased from a commercial vendor. As shown in Fig. 5F, wild
type P was phosphorylated by PLK1, while P-S308A was not,
indicating that S308 within P protein is the phosphorylation site of
PLK1.
PLK1 targets S308 of P in infected cells
Previously, mutations affecting P phosphorylation were identi-
fied and tested using in vitro or mini-genome assays. However, the
results were not substantiated when the sites are incorporated into
recombinant viruses. Thus, to determine whether phosphorylation
of P affects viral gene expression, it is essential to examine the
effects of putative mutations in the context of virus infection. Using
a PIV5 reverse genetics system, we generated two recombinant
viruses encoding mutant P proteins: rPIV5-V/P-S157A, which has
a single amino acid change in the PLK1 binding site; and rPIV5-
P-S308A, which has a single amino acid residue change at 308 at
the PLK1 phosphorylation site (Fig. 6A). The mutant viruses grew
to normal titers and formed plaques similarly to wt PIV5 (data not
shown). Viral gene expression levels from cells infected with the
viruses were examined by flow cytometry using anti-HN antibody.
As shown in Fig. 6B, cells infected by rPIV5-V/P-S157A or
rPIV5-P-S308A expressed higher levels of HN than PIV5-infected
cells, consistent with previous observations.
To investigate whether PLK1 phosphorylates the P protein at
S308 in infected cells, we performed
33P-orthophosphate labeling
of infected cells with or without BI 2536 treatment similar to the
experiment described in Fig. 4A. As shown in Fig. 6C and 6D, the
P protein in cells infected by rPIV5-P-S308A had lower levels of
phosphorylation than that in PIV5-infected cells. Phosphorylation
of P-S308A in infected cells was not sensitive to BI 2536 treatment
while phosphorylation level of wild type P was reduced by PLK1
inhibitor BI 2536, indicating that S308 is a phosphorylation target
for PLK1 in infected cells. These results mirror those presented in
Fig. 4 using rPIV5-Cpi+, whose P protein encodes Ser at position
308 but no longer binds PLK1 due to the S157F mutation,
underscoring the importance of both binding and phosphorylation
of P by PLK1.
Induction of apoptosis and cytokine expression by
mutant viruses
It has been reported that rPIV5-CPI2 virus, which contains a
mutation at S157, causes increased cell death and cytokine
expression in addition to the increased levels of viral gene
expression. To investigate whether recombinant PIV5 containing
these mutations described above cause increased cell death, MDBK
cells were infected and photographed. As shown in Fig. 7A, the
viruses causedincreased cell death.To further investigate thenature
of the cell death, apoptosis assays were performed on the cells
infected with mock, wild type, rPIV5-P-S308A or rPIV5-V/P-
S157A. Both mutant viruses induced increased apoptosis in the
infectedcellsusingpropidiumiodinestaining,whichdetectsthesub-
G0-G1 population, annexin V staining, which detects phosphati-
dylserine (PS) on the surface, and TUNEL assay, which detects
nicked DNA (Fig. 7B, C and D). To examine growth of
recombinant viruses in cultured cells, HeLa cells and Vero cells
were infected with recombinant viruses at low MOI and virus titers
in media of infected cells were determined at various times post-
infection by plaque assay. Interestingly, while rPIV5-V/P-S157A
and rPIV5-P-S308A grew fast than wild type initially as expected
since the mutant viruses had higher levels of viral gene expression,
their growth was reduced at later time points in HeLa cells, which
are capable of producing and responding to interferon. This drop of
growth was not observed in Vero cells, which do not produce
interferon (Fig. 7E), indicating that interferon may play a role in
growth of the viruses. To investigate induction of cytokines by the
mutant viruses, HeLa cells were infected and media from infected
cells were collected. Amounts of IFN-b, an anti-viral cytokine, and
IL-6, a proinflammatory cytokine, were measured using ELISA.
Expression levels of both cytokines wereelevated in rPIV5-P-S308A
and rPIV5-V/P-S157A-infected cells compared to mock or wild
type virus-infected cells (Fig. 7F and G).
Discussion
Our studies present the first evidence that phosphorylation of a
paramyxovirus P protein directly regulates viral gene expression.
Mutating phosphorylation sites within the P protein of SeV such
that P phosphorylation is reduced by more than 90% in
Figure 4. Effects of PLK1 inhibitor on phosphorylation of P. (A). Effects of BI 2536 on phosphorylation of P. Cells were mock-infected or
infected with PIV5 or rPIV5-CPI+. At 18–20 hours post infection, the cells were metabolically labeled with
35S-Cys/Met or
33P-orthophosphate in the
presence of 1 mM PLK1 inhibitor BI 2536 or DMSO as described in Experimental Procedures. The cells were lysed and immunoprecipitated with anti-P
Pk antibody. (B). Quantification of effects of BI 2536 on phosphorylation of P. Three individual experiments as described in (A) were quantified. The
average ratio of phosphorylated P from the
33P-labeling experiment to total amount of P as
35S-labeled P in PIV5 infected cells treated with DMSO
was set to 100 and the others are normalized to the ratio. The average of relative level of phosphorylation of P +/2 SEM is shown.
doi:10.1371/journal.ppat.1000525.g004
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in a mini-genome system or in recombinant virus [5]. Similarly,
mutation of the major phosphorylation sites within the P protein of
RSV results in a mutant P whose level of phosphorylation is
reduced by more than 90%. Yet, when these mutations are
introduced into the RSV genome by reverse genetics, expression
levels of the viral genes are not adversely affected. These results
seemingly suggest that phosphorylation of the P proteins of
paramyxoviruses does not have a role in viral gene expression.
However, it is possible that the critical phosphorylation sites within
the P proteins have not been identified in these earlier studies.
While it is true that some of the phosphorylation sites may be
superfluous and may not have a role in viral gene expression, it is
difficult to imagine that none of the phosphorylation sites within a
heavily phosphorylated P protein have any role in its function.
Even though mutation of known phosphorylation sites reduces
phosphorylation of SeV and RSV P by 90%, it is possible that the
remaining residues that are phosphorylated (even though they only
count for about 10% of total phosphorylation) are critical for viral
gene expression. In this work, we have identified a host kinase,
PLK1, which phosphorylates the P protein and mapped both its
binding (SSP motif at S157) and phosphorylation (S308) sites
within P. Further, we demonstrated that this site (S308) is
important in regulating viral gene expression using a recombinant
virus. To the best of our knowledge, this is the first report of a host
kinase that directly phosphorylates the P protein and regulates
viral gene expression of a paramyxovirus. Interestingly, PLK1
phosphorylation down-regulates viral gene expression, contrary to
our expectation that phosphorylation may be essential for viral
gene expression. It is possible that additional phosphorylation sites
within the P protein may play an essential role in the regulation of
viral gene expression. Previously, we have found that AKT1, a
serine/threonine kinase, plays a critical role in viral gene
expression [28]. However, direct interaction between P and
AKT1 as well as phosphorylation site of AKT within the P protein
has not been reported. Further studies of phosphorylation of the P
protein will be needed to identify possible phosphorylation sites
within P that are critical for viral gene expression.
Previously, we showed that S157 was phosphorylated and
contributes to the phenotypes of rPIV5-CPI2. However, it was
Figure 5. PLK1 phosphorylates the P protein at S308. (A). Prediction of PLK1 phosphorylation site within P protein. The center bold S/T residue
is the PLK1 phosphorylation site. X, any amino acid residue; Y, amino acid residue with a hydrophobic side chain. (B). Effect of mutating S308 into A
on the mini-genome activity. A mini-genome system as described before was used. To ensure a validity comparison of P vs. P-S308A, a range of
concentrations of the P proteins in the experiments were used. Cell lysate aliquots of the transfected cells were subjected to immunoblotting using
anti-NP or anti-P antibody. The average of relative luciferase activity +/2 SEM is shown. (C). Effects of PLK1 inhibitor on the mini-genome system
using P-S308A. To study the effect of PLK1 inhibitor on mini-genome activity with mutant P-S308A, BI 2536 was added to the mini-genome system
using P-S308A in a similar fashion as in Fig. 2D. (D). Effects of PLK1 overexpression on the mini-genome system using P-S308A. Plasmids encoding
pCAGGS-Flag-PLK1 at various concentrations were transfected along with the mini-genome system as above. Dual luciferase assay was carried as
described above. An aliquot of cell lysate was used for immunoblotting to detect expression levels of Flag-PLK1. (E). Interaction between P-S308A and
PLK1. A plasmid encoding Flag-PLK1 was transfected into cells with a plasmid encoding P or P-S308A. The cells were metabolically labeled and
immunoprecipitated with anti-P or anti-Flag. (F). Phosphorylation of P by PLK1 in vitro. HeLa cells were transfected with plasmids pCAGGS-P or
pCAGGS-P-S308A. P and P-S308A were purified from transfected cells using anti-P as described in Experimental Procedures. Kinase assays were
carried out in a total volume of 30 ml containing 100 ng PLK1 for 60 minutes at room temperature. The bottom panel is the input of P and P-S308A
with PLK1 on a SDS-PAGE with Coomassie blue staining.
doi:10.1371/journal.ppat.1000525.g005
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mutation, contributed to the CPI2 phenotypes since V and P are
identical in the first 164 amino acid residues. In this work, we have
identified a single amino acid residue (S308) within the P protein
as a PLK1 phosphorylation site. Mutating this phosphorylation
site has the same effect on viral gene expression as the CPI2 P
mutations, further confirming our previous report that the
increased gene expression from rPIV5-CPI2 is due to a P protein
that is more efficient in facilitating viral RNA synthesis since the
S308A mutation is within the unique P sequences while the V
remains intact. It may seem counterintuitive that a virus would
down-regulate its own gene expression by maintaining binding
and phosphorylation sites for PLK1. However, higher PIV5 gene
expression is associated with the induction of cytokine expression
and cell death, which in turn limits virus replication and spread.
Therefore, viruses that down-regulate their gene expression via
PLK1 phosphorylation of P would have advantages in viral
transmission over viruses with defective PLK1 binding or
phosphorylation sites (Fig. 8). Since increased cell death and
cytokine expression induced by virus infection limit virus
replication, it is possible that targeting PLK1 can enhance host
innate immune responses, leading to a novel strategy to control
virus infection. The lower viral gene expression after PLK1
phosphorylation may also favor persistent viral infection. Interest-
ingly, about half the strains of PIV5 have an S residue at position
157 [15].
PLK1 can phosphorylate proteins with a PLK1 binding domain
as well as a proteins associated with PLK1-binding proteins. Thus,
it is possible that PLK1 down-regulates viral gene expression
through phosphorylation of a P-binding protein. However, the
S308A mutant, which still binds PLK1, has the same viral gene
expression phenotype as PLK1 binding site (S157) mutants,
indicating that P is not merely a scaffold for PLK1 to down-
regulate viral gene expression, but is the target of PLK1 itself. The
exact mechanism of how the phosphorylation by PLK1 at residue
S308 affects the function of P remains to be determined. The P
protein does not have a catalytic domain but it plays an essential
regulatory role in viral gene synthesis. P is known to interact with
viral proteins NP and L. Binding to and phosphorylation by PLK1
do not appear to have an impact on the interactions between P
and NP or L. Previously, it has been reported that rPIV5-CPI2
has an increased viral RNA genome synthesis while viral mRNA
transcription is not affected [21]. It is possible that phosphoryla-
tion at S308 changes the conformation of P to make it less efficient
in facilitating viral RNA genome synthesis. It is possible that
phosphorylated P (at 308) binds to RNA better and increases the
rate of RNA synthesis. However, we cannot rule out the possibility
that phosphorylation of P at S308 may affect its ability to interact
with a yet-to-be identified host protein, which in turn regulates
viral gene expression.
A role for PLK1 in infection by other viruses has been reported
recently. Expression of human T-lymphotropic virus type-I
protein p30 reduces expression as well as phosphorylation of
PLK1 [29] while PLK1 is up-regulated in CD4+ T cells from
rhesus macaques infected with simian immunodeficiency virus
[30] as well as in cells expressing E6/E7 of human papillomavirus
Figure 6. Effect of mutating S to A at position 308 in recombinant virus. (A). Sequences of PIV5, rPIV5-V/P-S157A and rPIV5-P-S308A at
regions around residue 157 and 308 of the P protein. The entire genome of the mutant viruses was sequenced and no mutation was observed except
in the designated site (S157A or S308A). (B). Viral gene expression from PIV5, rPIV5-V/P-S157A and rPIV5-P-S308A-infected cells. HeLa cells were
infected with PIV5, rPIV5-V/P-S157A, or rPIV5-P-S308A. At 16 hours post infection, the infected cells were processed for flow cytometry using anti-HN
antibody as described in Experimental Procedures. Average mean fluorescence intensity of infected cells +/2 SEM is graphed. (C). Effects of PLK1
inhibitor on phosphorylation of P of rPIV5-P-S308A. Cells were mock-infected or infected with PIV5 or rPIV5-P-S308A. At 18–20 hours post infection,
the cells were metabolically labeled with
35S-Cys/Met or
33P-orthophosphate in the presence of 1 mM PLK1 inhibitor BI 2536 or DMSO as described in
Fig. 4A. The cells were lysed and immunoprecipitated with ant-P Pk antibody. (D). Quantification of effects of BI 2536 on phosphorylation of P of
rPIV5-P-S308A. Three individual experiments as described in (C) were quantified. The average ratio of phosphorylated P from the
33P-labeling
experiment to total amount of P as
35S-labeled P in PIV5 infected cells treated with DMSO was set to 100 and the others are normalized to the ratio.
The average of relative phosphorylation level of P +/2 SEM is shown.
doi:10.1371/journal.ppat.1000525.g006
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cells were infected with PIV5, rPIV5-V/P-S157A, or rPIV5-P-S308A. At 48 hours post infection, the infected cells were photographed using microscope
(Nikon ECLIPSE TE300, Japan). (B) Propidium iodine (PI) staining. MDBK cells were infected and collected 2 days post infection as above. The cells were
stained with PI and cellular DNA profiles were examined using flow cytometry. Percentages of sub G0-G1 population, which is considered apoptotic,
are graphed. S157A, rPIV5-V/P-S157A; S308A, rPIV5-P-S308A. (C). Annexin V staining. The infected cells were stained with FITC-labeled annexin V and
measured using a flow cytometer. Annexin V, which binds to phosphatidylserine (PS), is an indication of cells undergoing apoptosis when it is present
on cell surface. Percentages of annexin V positive cells are graphed. (D) TUNEL assay. The infected cells were subjected to a TUNEL assay as described
in Experimental Procedures. TUNEL positive cells were measured using a flow cytometer and percentages of TUNEL positive cells are graphed. (E).
Growth of recombinant viruses. HeLa cells or Vero cells were infected with viruses at 0.01 MOI and media of infected cells were collected at indicated
time points. Titers of viruses were determined using plaque assay. (F). Induction of IFN-b. HeLa cells were infected and levels of IFN-b were measured
using ELISA at 2 days post infection. (G). Induction of IL-6. HeLa cells were infected and levels of IL-6 were measured using ELISA at 2 days post
infection. Error bars are standard deviation of mean.
doi:10.1371/journal.ppat.1000525.g007
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human cytomegalovirus [32]. However, none of these studies has
demonstrated a direct role of PLK1 in viral gene expression and
the biological consequence of these studies are not clear. Recently,
Ludlow et al reported that the V protein of NiV contains a PLK1
binding site within the shared region of the NiV P protein and that
the PLK1 binding site is also involved in interacting with Stat1
protein, a key protein in IFN signaling [33]. However, the
biological consequence of this PLK1 interaction is not clear; since
Nipah virus is a biosafety level 4 pathogen, examining the role of
PLK1 in the context of Nipah virus infection is difficult. Ours is
the first report of PLK1 playing a direct role in virus replication.
The PLK1 binding site within the P protein of PIV5 is within
the shared region of the V and P protein; thus, the PIV5 V should
bind PLK1 as well. It is well known that the V protein blocks
interferon signaling by causing degradation of Stat1. However, it is
unlikely this PLK1 binding site is involved in interferon signaling
since the mutations at the S157 residue have no effect on IFN
signaling [19]. It is possible that PLK1 plays additional roles in
viral life cycle. For instance, PIV5 V protein is known to slow
down the cell cycle [34], so it is tempting to hypothesize that PLK1
is involved in the regulation of cell cycle by the V protein.
A cursory examination of the P proteins of paramyxoviruses
indicates that mostcontain SSP (or STP)sequence motifs; some of the
P proteins have more than one SSP sequence motif. For instance,
NiV P has two SSP sequences. However, it is not known whether
those S/T residues are phosphorylated. Since efficient PLK1 binding
requires the middle S/T residue to be phosphorylated [25], it is not
clear whether these SSP sequences are truly SSP motifs and bind
PLK1. It is possible that the role of PLK1 in viral gene expression is
universal for all paramyxoviruses. On the other hand, it is equally
possible that PLK1 plays different roles for different paramyxoviruses.
These questions warrant further investigation.
Materials and Methods
Plasmids, viruses, and cells
Plasmids expressing P mutants, Pcpi+, P-S157A and P-S308A
were made from a copy of P of W3A strain in the pCAGGS vector
[35]. The human PLK1 gene was obtained from Open Biosystems
(AL, USA). A Flag tag was added to the N-terminus of PLK1 and
cloned into pCAGGS vector. Kinase-deficient PLK1 (Flag-PLK1-
K82M) was constructed by PCR using Flag-PLK1 as the template
and pfx50
TM DNA polymerase (Invitrogen, 12355-012), and
confirmed by sequencing. Plasmids containing full-length genome
for rPIV5-V/P-S157A and rPIV5-P-S308A viruses were made
similarly to that of rPIV5-CPI+ as described before [21] and
confirmed by sequencing. Plasmids used in PIV5 mini-genome
system have been described before [21,36]. The details of plasmid
construction and sequences of the plasmids are available on
request. rPIV5-V/P-S157A and rPIV5-P-S308A were rescued
from the plasmids containing their respectively full-length genome
as described before [21]. PIV5, rPIV5-CPI+ and rPIV5-RL
viruses used in this study were described as before [21]. HeLa and
MDBK cells were grown in Dulbecco modified Eagle medium
(DMEM) (Invitrogen, USA) containing 10% fetal bovine serum
(FBS), 100 IU/ml penicillin, and 100 mg/ml streptomycin. BSR
T7 cells were grown in the same media as HeLa plus 10% tryptose
phosphate broth (TPB) and 400 mg/ml G418. All cell lines were
incubated at 37uCi n5 %C O 2. The growth medium for infected
cells contains only 2% FBS. Virus titers were determined using
BHK cells as described before [37,38].
Figure 8. A working model for regulation of PIV5 viral gene expression by PLK1. For wild type PIV5, PLK1 binds to SSP motif (156–158)
within the P protein, and then phosphorylates the P protein at S308, resulting in inhibition of PIV5 gene expression. The reduced viral gene
expression supports efficient virus replication, but enables virus to avoid the induction of cell death and cytokine expression. For rPIV5-CPI+, SSP is
mutated to SFP, preventing the binding of P to PLK1 and, thus, no phosphorylation of S308 by PLK1. As a result, viral gene expression is higher than
that of PIV5, and cell death as well as cytokine production is induced, resulting in limiting replication and spread of virus. However, when PLK1 is over
expressed, PLK1 can interact with S157F weakly through STP centered at T108 and reduces P-S157F mini-genome expression moderately. For rPIV5-P-
S308A, while the SSP motif is intact and P-S308A still binds to PLK1; however, there is no phosphorylation of S308. This mutant virus, similar to rPIV5-
CPI+, shows elevated viral gene expression and increased induction of cell death.
doi:10.1371/journal.ppat.1000525.g008
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MDBK cells were infected with mutant virus stock with MOI of
1. At two days post infection, viral RNA was extracted from the
media by QIAmp viral RNA mini kit (Qiagen, CA) following the
protocol provided by the manufacture. The viral RNA was reverse
transcribed with random primer (Superscript III first-Strand
Synthesis System, Invotrogen). 12 pairs of oligomers were used
for PCR and 30 oligomers were used for sequencing. The terminal
sequences of viral genome were obtained by Rapid Amplification
of cDNA Ends (RACE) as described before [39]. Briefly, to
sequence 39 leader sequence, viral RNA was ligated with an
adaptor JX129 then reverse transcribed by JX130 (complementary
to JX129). The cDNA were amplified by the JX130–JX131 pair
and then sequenced. To sequence 59 trailer sequence, the viral
RNA was firstly reverse transcribed using JX133. The cDNA
products were purified and ligated to JX129. The ligation product
was amplified with JX130–JX132. The PCR products were
purified, sequenced and compared with wide type PIV5 genome
using BLAST. Sequences of all oligomers used for PCR or
sequencing are available on request.
Immunoprecipitation
To detect interactions between P and endogenous PLK1 in
infected cells, HeLa cells in 10 cm plates were infected with mock,
PIV5 or rPIV5-CPI+ at multiplicity of infection (MOI) of 3 for 12 h
then treated with 100 ng/ml Nocodazole, which is known to increase
expression levels of PLK1 by arresting cells into M phase when PLK1
expression levels are the highest [40–42]. After10–12 h incubation
with Nocodazole, the cells were lysed by Whole Cell Extraction
Buffer (WCEB: 60 mM Tris-HCl pH 6.8, 40% glycerol, 4%SDS,
3% dithiothreitol (DTT), and few grains of bromophenol blue)
containing protease inhibitor cocktail as described before [21,43].
The same amount of the lysates were pre-cleared with 40 mlp r o t e i n
Gs e p h a r o s eb e a d sf o r1ha t4 uC. The cell lysate were then incubated
with P antibody and 30 ml protein G sepharose beads for 2–3 h at
4uC. The precipitated proteins were resolved by 15% sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS-PAGE), and trans-
ferred onto PVDF membrane (Milipore, MA). Mouse anti-PLK1
antibody (Santa Cruz Biothechnology) was used to detect PLK1 by
immunoblotting as described before [21,43]. To examine whether
PLK1 interacts with P directly, not through other viral proteins, BSR
T7 cells in 6 cm plates were transfected with pCAGGS vector,
pCAGGS-P, or pCAGGS-Pcpi+ with pCAGGS-Flag-PLK1 using
Plus and Lipofectamine reagents following the protocol from
manufacturer (Invitrogen). The transfected cells were incubated with
DMEM deficient of Cys/Met for 30 minutes and then labeled with
DMEM containing
35S-Cys/Met Promix (Amersham Life Sciences)
(100 mCi/ml) for 3 h. The cells were lysed in RIPA buffer (20 mM
Tris-HCl pH 7.4, 150 mM NaCl, 0.2% Triton-X100, 0.1% SDS,
5 mM Iodoacetanide) containing protease inhibitor cocktail. Pk
antibody or Flag antibody together with Protein G sepharose beads
were used for immunoprecipitation. The precipitated proteins were
washed three times with RIPA buffer containing 0.3 M NaCl and
once with RIPA buffer containing 0.15 M NaCl. After washing, the
precipitated proteins were resolved by 15% SDS-PAGE, and proteins
were detected by autoradiography using Storm Phosphorimager
(Molecular Dynamics Inc., Sunnyvale, CA).
PLK1 inhibitors
BI 2536, a highly selective PLK1 inhibitor was purchased from
Axon Company (The Netherlands) [41]. The compound was
dissolved in dimethyl sulfoxide (DMSO). To study the effect of
PLK1 inhibitor on rPIV5-RL gene expression, HeLa cells or BSR
T7 cells at about 90% confluence were infected with rPIV5-RL at
a MOI of 1 and incubated with the media containing 2% FBS and
PLK1 inhibitor. Renilla luciferase activity was examined by
luminometer using Renilla luciferase assay kit (Promega) at 16 to
20 hours post infection. Similarly, BI 2536 was tested in the mini-
genome system. GW843682 (Sigma), a PLK1 inhibitor, which
inhibits PLK1 and weakly inhibits PLK3 (which has similar
function as PLK1) [44], was also used.
Phosphorylation of P
To examine phosphorylation of P, infected cells in 6 cm plates
were incubated in the medium lacking sodium phosphate for
30 minutes and then labeled with medium containing
33P-
orthophosphate (100 mCi) in the present of DMSO or 1 mMB I
2536 for 4 hour. The cells were then lysed, immunoprecipitated
using Pk antibody, and resolved in 15% SDS-PAGE and
quantified as before.
PIV5 mini-genome system and dual luciferase assay
PIV5 mini-genome system used in this study was described
before [21], except that negative controls contained no P plasmid,
instead of no L plasmid. BSR T7 cells in 24-well plates were
transfected with plasmids expressing pSMG-RL (0.2 mg), NP
(0.2 mg), P (0.01–0.16 mg), L (0.3 mg) as well as a firefly luciferase
gene (FF-Luc) under control of a T7 promoter using Plus and
Lipofectamine reagents (Invitrogen). GFP plasmid was used as a
control to keep the total amount of transfected plasmids the same.
For transfection of Flag-PLK1 or Flag-PLK1-K82M together with
the mini-genome system composed of P, P-S157A orP-S308A, P
or P mutant plasmids were used at 0.02 mg. At 18–22 hrs post
transfection, the cells were lysed with 100 ml1 6passive lysis buffer
(Promega). 10 ml lysate from each well were used for dual
luciferase assay by dual luciferase assay kit (Promega). Ratios of R-
Luc to FF-Luc activity are normalized as relative activity unit. Six
replicates of each sample were used for statistical analysis. An
aliquot of the cell lysate from mini-genome system was mixed with
equal volume of 26 protein lysis buffer as described before.
Samples were resolved in 10% SDS-PAGE and transferred onto
PVDF membrane. Mouse anti-NP and mouse anti-P (Pk antibody)
were used together for immunoblotting. Anti-Flag was used to
detect the amount of input of Flag-PLK1 or Flag-PLK1-K82M.
In vitro kinase assay
For PLK1 in vitro kinase assay, HeLa cells in 10 cm plates were
transfected with pCAGGS-P-wt or pCAGGS-P-S308A. At
24 hours post transfection, anti-V5 agarose gel, which has Pk
antibody conjugated to the agarose beads, was used to purify P-wt
or P-S308A using immunoprecipitation. Similar amounts of P-wt
and P-S308A were used for PLK1 (Cell Signal, MA) in vitro kinase
assay with kinase buffer (25mMHEPES, 25 mM beta-glycero-
phosphate, 25 mM MgCl2, 2 mM dithiothreitole, and 0.1 mN
NaVO3). Half of the reaction mixture was used for SDS-PAGE
followed by Coomassie blue staining to measure the amount of
input P-wt and P-S308A, and the other half of the mixture was
incubated with 10 mCi c-
32P-ATP (Amersham Biosciences) for 1 h
at room temperature in a total volume of 30 ul containing 100 ng
PLK1. Reactions were terminated by addition of the same volume
of 26SDS loading buffer. Proteins were separated by 15% SDS-
PAGE and phosphorylation was detected with a Storm Phosphor-
Imager (Molecular Dynamics).
Flow cytometry
To detect different levels of viral gene expression in Mock,
PIV5, rPIV5-P-S308A, and rPIV5-V/P-S157A infected cells, flow
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HeLa cells at about 90% confluence were mock infected or PIV5,
rPIV5-V/P-S157A, or rPIV5-P-S308A infected at MOI of 3. The
infected cells were collected at 16 h hpi and fixed with 0.5%
formaldyhyde for 2 h at 4uC. After centrifugation and removal of
the supernatant, the cells were re-suspended in 500 ml solution of
FBS-DMEM (50:50), then permeabilized in 70% ethanol
overnight at 4uC. The cells were washed with phosphate buffered
saline without Mg
2+ and Ca
2+ (PBS-) and incubated with mouse
anti-HN in PBS- with 10% FBS for 30 min at room temperature.
After washing with PBS-, the cells were further stained with FITC-
conjugated goat anti-mouse antibody in the dark and washed with
PBS-. The fluorescence intensity was measured using a flow
cytometer (FC500).
Apoptosis assays
To detect apoptotic cells, annexin-V staining, propidium iodide
(PI) staining, and terminal deoxynucletidyltransferase-mediated
dUTP-FITC nick end labeling (TUNEL) assay were performed as
previously described [45,46]. Briefly, MDBK cells in 6-well plates
were infected with Mock, PIV5, rPIV50P-S308A or rPIV5-V/P-
S157A with MOI of 5 for 48 h. The floating cells were harvested
together with the trypsinized monolayer cells. For annexin-V
staining, the cells were washed with cold PBS- and incubated with
FITC-labeled annexin-V (Annexin-V-FLIOS, Roche Diagnostics
Corp. Mannheim, Germany) for 15 min at room temperature.
10,000 cells were examined for fluorescence by a flow cytometer
FC500. For PI staining, the collected cells were fixed and
permeabilized as before. The permeabilized cells were washed
and incubated with 100 ml Pk antibody (1:100 dilution in PBS-1%
BSA) for 30 min at room temperature. After washing, the cells
were incubated with 100 ml FITC-labeled anti-mouse antibody
(1:1,000 in PBS-1%BSA). The cells were finally incubated with
500 ml of PI solution (50 mg/ml) (Sigma-Aldrich). The stained cells
were examined with a flow cytometer. For TUNEL assay, the
permeabilized cells were incubated with 25 ml of TUNEL reaction
mixture (Roche Diagnostics Corp. Mannheim, Germany) for 3 h
in the dark at 37uC. After washing, the cells were incubated with
100 ml Pk antibody (1:100 dilution in PBS-1% BSA) then 100 ml
Phycoerythrin-labeled anti-mouse antibody (1:100 dilution in
PBS-1%BSA) and analyzed with FC500.
Enzyme-linked immunosorbent assay (ELISA) for IFN-b
and IL-6
HeLa cells infected with mock, PIV5, rPIV5-P-S308A, rPIV5-
V/P-S157A were infected with MOI of 5. The media were
collected at 48 h post infection and centrifuged to remove cell
debris. 50 ml cleared media or IFN-b standard in duplicate were
used for IFN-b ELISA by using human IFN-b ELISA kit (PBL
InterferonSource, NJ). For IL-6 production, the same media
samples were sent to The General Clinical Research Center
(GCRC) at Pennsylvania State University to measure IL-6 as
described in Lin et al [47].
Supporting Information
Figure S1 Interaction between PLK1 and Pcpi+. The cells were
transfected as in Fig. 1B. However, the cells were not metabolically
labeled and immunoprecipitated as in Fig. 1B. The immunopre-
cipitated peptides were resolved in SDS-PAGE and subjected to
immunoblotting using antibodies against P or PLK1.
Found at: doi:10.1371/journal.ppat.1000525.s001 (0.84 MB TIF)
Figure S2 Effect of PLK1 inhibitor GW843682 on PIV5 gene
expression. GW843682 (Sigma), a PLK1 inhibitor, was examined.
HeLa cells in 24-well plates were infected with rPIV5-RL at MOI
of 1 and incubated with GW843682 at 37uC for 16 to 20 hours.
Luciferase activities from the cells were measured as described in
Fig. 2A. The average of relative luciferase activity +/2 SEM is
shown.
Found at: doi:10.1371/journal.ppat.1000525.s002 (0.74 MB TIF)
Figure S3 Effects of P with S changed to A at position 157 (P-
S157A). (A). Interaction between P-S157A and PLK1. A plasmid
encoding Flag-PLK1 was transfected into cells with a plasmid
encoding P or P-S157A. The cells were metabolically labeled and
immunoprecipitated with anti-P or anti-Flag. (B). Effects of PLK1
overexpression on the mini-genome system using P-S157A.
Plasmids encoding pCAGGS-Flag-PLK1 at various concentra-
tions were transfected along with the mini-genome system. An
aliquot of cell lysate was used for immunoblotting to detect
expression levels of Flag-PLK1. The average of relative luciferase
activity +/2 SEM is shown.
Found at: doi:10.1371/journal.ppat.1000525.s003 (2.43 MB TIF)
Figure S4 Effects of mutating serine residues close to the serine
residue at position 308 of P on mini-genome gene expression. (A).
Comparison of the mini-genome activity of P to that of P with a S
to A change at position 304. (B). Comparison of the mini-genome
activity of P to that of P with a S to A change at position 313. The
average of relative luciferase activity +/2 SEM is shown.
Found at: doi:10.1371/journal.ppat.1000525.s004 (1.26 MB TIF)
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